HuR deficiency abrogated the enhanced NLRP3 signaling in experimental ischemic stroke
The FASEB Journal · 15.01.2024 · 38 (1)
DOI: 10.1096/fj.202300812r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023-12. Verfasst von Xiaojie Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Brain Ischemia, Ischemic Stroke, Reperfusion Injury. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Sciences and Technology Project of Jinan.
Themen: Schlaganfall
Abstract (Originalsprache)
Human antigen R (HuR) is a universally expressed RNA‐binding protein that plays an essential role in governing the fate of mRNA transcripts. Accumulating evidence indicated that HuR is involved in the development and functions of several cell types. However, its role in cerebral ischemia/reperfusion injury (CIRI) remains unclear. In this study, we found that HuR was significantly upregulated after CIRI. Moreover, we found that silencing HuR could inhibit the inflammatory response of microglia and reduce the damage to neurons caused by oxygen–glucose deprivation/reperfusion treatment. In vivo, we found that microglial HuR deficiency significantly ameliorated CIRI and reduced NLRP3‐mediated inflammasome activation. Mechanistically, we found that HuR could regulate NLRP3 mRNA stability by binding to the AU‐rich element (ARE) region within the 3′ untranslated region (UTR) of NLRP3 mRNA. In addition, we found that the upregulation of HuR was dependent on the upregulation of NADPH oxidase‐mediated ROS accumulation. Collectively, our studies revealed that HuR could regulate NLRP3 expression and that HuR deficiency abrogated the enhanced NLRP3 signaling in experimental ischemic stroke. Targeting HuR may be a novel therapeutic strategy for cerebral ischemic stroke treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China.
- Department of Pathology, Binzhou Medical University, Binzhou, China.
- Cisen Pharmaceutical Co., Ltd, Jining, China.
- Institute of Pathology and Pathophysiology, School of Basic Medical Sciences, Binzhou Medical University, Yantai, China.
- Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
ORCID-Profile: Xiaojie Wang, Mingfeng Zhao, Xiulian Lu, Pengchao Du, Shaobin Feng, Ruo Gong, Hao Chen, Guoliang Qi, Fan Yang
Förderung
- Natural Science Foundation of Shandong Province
- Sciences and Technology Project of Jinan
Zitieren
APA
Wang, X., Zhao, M., Lu, X., Du, P., Feng, S., Gong, R., Chen, H., Qi, G., & Yang, F. (2024). HuR deficiency abrogated the enhanced NLRP3 signaling in experimental ischemic stroke. The FASEB Journal, 38(1). https://doi.org/10.1096/fj.202300812r
Vancouver
Wang X, Zhao M, Lu X, Du P, Feng S, Gong R, et al. HuR deficiency abrogated the enhanced NLRP3 signaling in experimental ischemic stroke. The FASEB Journal. 2024;38(1). doi:10.1096/fj.202300812r
BibTeX
@article{Wang2024,
author = {Wang, Xiaojie and Zhao, Mingfeng and Lu, Xiulian and Du, Pengchao and Feng, Shaobin and Gong, Ruo and Chen, Hao and Qi, Guoliang and Yang, Fan},
title = {HuR deficiency abrogated the enhanced NLRP3 signaling in experimental ischemic stroke},
journal = {The FASEB Journal},
year = {2024},
volume = {38},
number = {1},
doi = {10.1096/fj.202300812r}
}
EUVIMED